R3 Bio pitched brainless human clones for spare body parts

Silicon Valley billionaires have funded plenty of eccentric anti-aging ideas, from hyperbaric chambers to parabiosis blood transfusions. But California biotech startup R3 Bio has taken the longevity obsession into full dystopian territory.

MIT Technology Review revealed that R3 Bio has been quietly pitching private investors on an ethically explosive premise: growing nonsentient, brainless human clones to serve as personalized organ farms and living backup bodies for wealthy clients. Under founder John Schloendorn's theoretical vision, clients could harvest immune-matched spare organs or even transplant their aging brain into a young, headless clone body to kick off a second lifespan.

Publicly, the Richmond-based startup told a completely different story. Just last week, R3 announced in Wired that it had emerged from stealth after raising funds from billionaire Tim Draper, Singapore fund Immortal Dragons, and LongGame Ventures. But R3 framed its mission strictly around creating nonsentient monkey "organ sacks" to replace animals in drug testing, keeping its human clone roadmap firmly behind closed doors.

Pitching body replacement behind closed doors

Despite R3's formal denials that it ever intended to clone humans or solicit surrogates, reporters uncovered a trail of private meetings and roadmaps that told another tale. Just last September, Schloendorn and cofounder Alice Gilman presented at Abundance Longevity, an exclusive $70,000-per-ticket conference in Boston organized by Peter Diamandis. In a private session titled "Full Body Replacement," the founders reportedly discussed personal clones for spare organs while standing before a slide of a cloning needle.

Schloendorn's technical rationale drew inspiration from rare congenital conditions where infants survive with only a brainstem, lacking cerebral hemispheres. His pitch argued that gene-edited human bodies lacking higher brain structures would have no consciousness or pain perception, theoretically clearing the moral hurdles of organ harvesting.

Because artificial wombs do not exist, Schloendorn reportedly suggested the first generation of brainless clones would have to be gestated by paid surrogate mothers. One attendee described the pitch as an unnerving collision between a close encounter of the third kind and Dr. Strangelove.

While there is no evidence R3 has successfully cloned anything larger than a rodent, the startup mapped out technical diagrams for creating brainless animals and sought to run monkey trials from an offshore base in the Caribbean.

Mainstream researchers pushed back fiercely. Jose Cibelli, a cloning pioneer at Michigan State University, warned that attempting to manufacture an abnormal human crosses an absolute moral line. Even one of R3's own backers, Boyang Wang of Immortal Dragons, admitted after investing $500,000 that whole-body transplants remain practically infeasible and barely scientific.

Why it matters

Longevity funding is increasingly spilling over from rigorous preventive medicine into fringe transhumanist fantasies.

For everyday patients waiting on donor lists, R3 Bio offers zero practical help. True whole-body replacement remains a biological dead end with current tech; severed spinal cords cannot be reconnected, as demonstrated by Russian head-transplant trials on pigs that ended in complete paralysis. Even if partial organ harvesting worked, custom cloning and surrogate gestation would remain an exorbitant luxury reserved exclusively for the ultra-wealthy.

For the biotech sector, ventures like R3 risk triggering a massive public and regulatory backlash. Legitimate regenerative medicine is already making steady progress using lab-grown organoids, synthetic tissues, and gene-edited pig organs. Courting capital to grow headless human bodies creates a public relations hazard that could easily provoke sweeping bans across broader embryo and tissue research.

In our view, pitching headless human clones as a medical workaround reveals a glaring moral and technical blind spot. Treating the human frame as an interchangeable chassis while trying to skirt personhood definitions through engineered brain damage is bad science wrapped in extreme longevity panic. Betting millions on a dystopian shortcut won't defeat aging, but it will certainly accelerate the regulatory crosshairs coming for stealth biotech.